



## June 2017 Newsletter

Volume 5, Issue 6

### A Letter from the Founder, Dr. Christine Brezden- Masley

Dear CCTC Members,

Since the launch of the CCTC in 2011, the consortium has remarkably expanded to over 260 members across 31 institutions, including 12 of the major cancer centres in Ontario.

We greatly value any input, feedback, and suggestions in order to make your experience with the site as user-friendly as possible. E-mail us at [cometrials@smh.ca](mailto:cometrials@smh.ca) and we will be more than happy to assist.

Sincerely,

Dr. Christine Brezden-Masley  
Founder, CCTC

### A Letter from the Project Manager, Caroline Illmann

Hello CCTC Members,

This year we are focusing on increasing membership and trials posted. Please feel free share CCTC with your oncology colleagues, we are always happy to have new members join the CCTC network. CCTC is continuing to grow with over 270 members and 31 institutions.

If you have an accruing trial you would like to highlight, please email [cometrials@smh.ca](mailto:cometrials@smh.ca) to nominate it to be one of our next *Trials of the Month*.

As always, please contact me at [cometrials@smh.ca](mailto:cometrials@smh.ca) any time with questions, comments or concerns.  
Kind Regards,

Caroline Illmann  
Project Manager, CCTC

## ARTICLE RECOMMENDATION

### Accrual of older adults to Canadian Cancer Trials Group (CCTG) led trials: A retrospective analysis from 1990 to 2015

Catalina Hernandez Torres, Winson Y. Cheung, Christopher J. O'Callaghan, Tina Hsu

DOI: [10.1200/JCO.2017.35.15\\_suppl.10031](https://doi.org/10.1200/JCO.2017.35.15_suppl.10031)

**Background:** Older adults (OA) age 65+ make up to 60% of all newly diagnosed cancers. However, only 22-32% of patients accrued in cooperative group studies in the 1990s were age 65+. In 2003, several studies suggested that clinical trial design, in particular the presence of strict exclusion criteria, was a major barrier to accrual of OA. The objective of this study was to determine: 1) whether there has been an improvement in accrual of OA to clinical trials led by the Canadian Cancer Trials Group (CCTG) over time; 2) clinical trial features associated with accrual of OA to clinical trials 3) whether exclusion criteria in trials initiated 2003 or after have been relaxed. **Methods:** All completed randomized Phase II and III CCTG-led clinical trials initiated between 1990 or later were included. Trial characteristics including tumor type, stage, treatment type, and exclusion/inclusion criteria, as well as percentage of OA age 65+ accrued were recorded. Association between percentage of OA accrued and trial characteristics were compared using the Wilcoxin rank sum test. Assessment of exclusion criteria before and after 2003 was compared using the Chi Square test or Fisher exact test. **Results:** A total of 68 trials were included. Most trials were phase III (73%), chemotherapy trials(48%), opened before 2003 (70.6%), advanced disease (73%) and lung cancer was the most common tumour site (17.6%). OA accrual remains low compared to OA diagnosed with cancer in Canada (41% vs. 56%,  $p < 0.001$ ). There was an improvement in accrual of OA after 2003 (47.1% vs. 34.9%,  $p = 0.02$ ). Tumour site, early stage disease, more restrictive performance status, requiring a new biopsy, and having a longer consent form, were associated with lower accrual of OA ( $p < 0.05$ ). There was no significant loosening of exclusion with time though patients with pulmonary comorbidities were more likely to be excluded in studies initiated in 2003 or later ( $p = 0.006$ ). **Conclusions:** OA remain under-represented in clinical trials. There has been no relaxing of exclusion criteria; however, exclusion based on comorbidities was not significantly associated with under accrual of OA in our study.

## TRIALS SNAPSHOT

Trial Type	Any Malignancy	Breast	CNS	GI	GU	GYN	Head & Neck	Heme	Lung	Mel	Total
Imaging Study	-	-	-	-	1	-	-	-	-	-	1
Observational	1	2	-	-	1	1	-	1	-	-	6
Prevention	-	-	-	1	-	-	-	1	-	-	2
Radiation	-	4	-	3	4	-	1	-	6	-	18
Supportive Care	1	4	-	-	-	-	-	-	-	-	5
Surgical Therapy	-	1	1	-	1	1	-	-	1	-	5
Systemic Therapy	1	13	1	13	14	4	1	15	12	7	80
Therapeutic	-	1	-	-	3	-	-	2	-	-	6
<b>TOTAL</b>	<b>3</b>	<b>25</b>	<b>2</b>	<b>17</b>	<b>24</b>	<b>6</b>	<b>2</b>	<b>19</b>	<b>19</b>	<b>7</b>	<b>123</b>



## June 2017 Newsletter

Volume 5, Issue 5

### TRIALS OF THE MONTH

Type	Acronym	Study Title	Description	Site(s)
Breast	<a href="#"><u>OLYMPIA (MA.36)</u></a>	A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy	<ul style="list-style-type: none"> <li>• HER2 Negative</li> <li>• Adjuvant</li> <li>• Systemic Therapy</li> </ul>	Odette Cancer Centre
GU	<a href="#"><u>PCS VI</u></a>	Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy Followed by HDR Brachy Boost for High Risk Adenocarcinoma of the Prostate (PCS-VI)	<ul style="list-style-type: none"> <li>• Prostate Cancer</li> <li>• Adjuvant</li> <li>• Radiation Therapy</li> </ul>	London Health Sciences Centre
Heme	<a href="#"><u>MYX1</u></a>	A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies	<ul style="list-style-type: none"> <li>• Multiple Myeloma</li> <li>• Relapse</li> <li>• Systemic Therapy</li> </ul>	Kingston General Hospital
GYN	<a href="#"><u>OVC.1/NRG GY004</u></a>	A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	<ul style="list-style-type: none"> <li>• Ovarian</li> <li>• Metastatic</li> <li>• Systemic Therapy</li> </ul>	London Health Sciences Centre
Lung	<a href="#"><u>MEDI4736</u></a>	A Randomized Trial of Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With High-Risk Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	<ul style="list-style-type: none"> <li>• Non-Small Cell</li> <li>• Metastatic</li> <li>• Systemic Therapy</li> </ul>	Humber River Regional Hospital Kingston General Hospital
Mel	<a href="#"><u>Trilogy</u></a>	A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFV600 Mutation-Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma	<ul style="list-style-type: none"> <li>• Melanoma</li> <li>• Stage III/IV</li> <li>• Systemic Therapy</li> </ul>	London Health Sciences Centre
GI	<a href="#"><u>CO.26</u></a>	A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies	<ul style="list-style-type: none"> <li>• Colorectal</li> <li>• Metastatic</li> <li>• Systemic Therapy</li> </ul>	Kingston General Hospital Odette Cancer Centre Royal Victoria Regional Cancer Centre



[Click here to NOMINATE your trial for Trials of the Month!](#)



## MEMBERSHIP UPDATES

**273 members**

**31 institutions**

**123 accruing trials**



## ACKNOWLEDGEMENTS

The CCTC has been funded by unrestricted educational grants from the following supporters:



## CONTACT US

Do you have any questions, feedback, suggestions? Please do not hesitate to contact us.

30 Bond Street  
Toronto, ON Canada  
M5B 1W8

[cometrials@smh.ca](mailto:cometrials@smh.ca)  
(416) 809-3915

[@COMET\\_Trials](https://twitter.com/COMET_Trials)  
[www.cometrials.com](http://www.cometrials.com)

## INSTITUTIONS

Institution	Location	Members	Trials
Cambridge Memorial Hospital	Cambridge	3	2
Grand River Hospital	Waterloo	9	1
Humber River Regional Hospital	Toronto	5	3
Kingston General Hospital	Kingston	4	28
Juravinski Cancer Centre	Hamilton	7	-
Lakeridge Health Corporation	Oshawa	20	-
London Health Sciences Centre	London	9	62
Mackenzie Health Hospital	Richmond Hill	6	-
Markham Stouffville Hospital	Markham	4	1
Mount Sinai Hospital	Toronto	2	4
North York General Hospital	Toronto	12	5
Odette Cancer Centre/Sunnybrook	Toronto	57	45
Ontario Institute for Cancer Research	Toronto	4	-
Ontario Hospital		1	-
Ottawa Hospital	Ottawa	2	-
Princess Margaret Cancer Centre	Toronto	25	1
Quinte Health Care	Belleville	1	-
Rouge Valley Health System	Ajax	3	-
Royal Victoria Regional Health Centre	Barrie	24	23
Scarborough General Hospital	Toronto	1	-
Southlake Regional Health Centre	Newmarket	19	12
St. Joseph's Health Centre	Toronto	4	-
St. Joseph's Healthcare	Hamilton	4	-
St. Michael's Hospital	Toronto	13	6
Sudbury Regional Hospital	Sudbury	1	-
Thunder Bay Regional	Thunder Bay	2	-
Toronto General Hospital	Toronto	3	1
Toronto East General Hospital	Toronto	6	-
Trillium Health Partners	Mississauga	16	-
William Osler Health Systems	Brampton	4	-
Windsor Regional Hospital	Windsor	1	-
Wingham and District Hospital	Wingham	1	-